AI in agritech: protecting innovation in a growing sector
28 October 2025
Artificial intelligence is reshaping the agricultural landscape. From early disease detection to waste reduction, AI is enabling more sustainable and…
Hot chips! Will patents become more important in the semiconductor industry?
27 October 2025
The excitement surrounding today’s most innovative AI tools is increasingly putting a spotlight on some of the key players in…
Added matter at the UPC: Samsung succeeds in revocation of Headwater patents
06 October 2025
Samsung has emerged triumphant in revocation counterclaims against Headwater’s patents EP3110069 and EP2391947 at the UPC’s Düsseldorf and Munich Local…
Quantum advantage: near-term breakthrough or long-term challenge?
25 September 2025
Quantum computing providers are engaged in a race to be the first to demonstrate quantum advantage (also referred to as…
Don’t jump the gun: preliminary injunction granted in 17 UPC states against generic pharmaceutical company
24 September 2025
In a recent order, the UPC Court of Appeal granted Boehringer Ingelheim provisional measures against generics company, Zentiva, for its…
Clean maritime: charting the course for greener shipping
16 September 2025
Shipping is the backbone of global trade, with the European Environment Agency estimating that 77% of European external trade is…
G1/24 practice points: clarity on claim interpretation principles
19 August 2025
G1/24 is of wide-ranging relevance as it provides clarity on the principles of claim interpretation, with the European Patent Office’s…
Patenting in an era of infrastructure renaissance: insights from Europe
12 August 2025
In 2025, Germany amended its constitution to create a staggering €500 billion fund for infrastructure modernisation. This is the largest…
G 1/25 referral: is it necessary to amend the description of the European patent?
07 August 2025
In G 1/25, questions have been referred to the Enlarged Board of Appeal to clarify whether it is necessary to…
History, opportunities and challenges for protecting gene therapies: perspectives from private practice and industry
01 August 2025
Recent years have seen an explosion of advanced therapies, many of which are based on personalised immune cells, individually edited…
G 1/23 and enablement: are commercially available products state of the art?
01 August 2025
In this eagerly awaited European Patent Office (EPO) decision, the Enlarged Board of Appeal concluded that a product put on…
Page 1 of 83
Next Page